Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8OWV

H6 and F2 nanobodies bound to SARS-CoV-2 spike RBD

This is a non-PDB format compatible entry.
Summary for 8OWV
Entry DOI10.2210/pdb8owv/pdb
DescriptorSpike protein S1, F2, H6, ... (6 entities in total)
Functional Keywordsnanobody, complex, receptor binding domain, sars-cov-2, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2
More
Total number of polymer chains3
Total formula weight53686.81
Authors
Mikolajek, H.,Naismith, J.H.,Owens, R.J. (deposition date: 2023-04-28, release date: 2024-05-08, Last modification date: 2024-10-09)
Primary citationCornish, K.,Huo, J.,Jones, L.,Sharma, P.,Thrush, J.W.,Abdelkarim, S.,Kipar, A.,Ramadurai, S.,Weckener, M.,Mikolajek, H.,Liu, S.,Buckle, I.,Bentley, E.,Kirby, A.,Han, X.,Laidlaw, S.M.,Hill, M.,Eyssen, L.,Norman, C.,Le Bas, A.,Clarke, J.,James, W.,Stewart, J.P.,Carroll, M.,Naismith, J.H.,Owens, R.J.
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
Open Biology, 14:230252-230252, 2024
Cited by
PubMed Abstract: The Omicron strains of SARS-CoV-2 pose a significant challenge to the development of effective antibody-based treatments as immune evasion has compromised most available immune therapeutics. Therefore, in the 'arms race' with the virus, there is a continuing need to identify new biologics for the prevention or treatment of SARS-CoV-2 infections. Here, we report the isolation of nanobodies that bind to the Omicron BA.1 spike protein by screening nanobody phage display libraries previously generated from llamas immunized with either the Wuhan or Beta spike proteins. The structure and binding properties of three of these nanobodies (A8, H6 and B5-5) have been characterized in detail providing insight into their binding epitopes on the Omicron spike protein. Trimeric versions of H6 and B5-5 neutralized the SARS-CoV-2 variant of concern BA.5 both and in the hamster model of COVID-19 following nasal administration. Thus, either alone or in combination could serve as starting points for the development of new anti-viral immunotherapeutics.
PubMed: 38835241
DOI: 10.1098/rsob.230252
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.73 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon